Building Pharmaceutical Outsourcing Partnerships

Immunomedics’s chemistry, which involves a maleimide group on one end of the linker, allows for attaching up to eight drug molecules per antibody site-specifically at reduced interchain disulfides while avoiding the formation of dimers and aggregates. The pH-sensitive, cleavable linkage is moderately stable, with the potential to release SN-38 in the acidic tumor microenvironment and increase the drug’s bioavailability. Together, these features allow for reduced toxicity, higher antibody doses, repeated therapy cycles, and a better therapeutic window, Immunomedics says.

Source :

Building pharmaceutical outsourcing partnerships
The Pharma Industry -- Transactional Outsourcing and Strategic Partnerships: An Insider's Perspective
Outsourcing: A Year in Review
The thinking process behind biopharma companies’ outsourcing management
Deloitte Predicts Pharma Growth Driven by Orphan Disease Drugs and External Deals
Faces of Philanthropy 2019: Great partnerships between businesses and nonprofits
Three stories of pharmaceutical outsourcing
Letco Med, L.L.C. Announces Partnership with ARL Bio Pharma to Launch Quality Savings Program for Compounding Pharmacists
A Voice of Their Own
Secure Your Place in the Hub of Pharmaceutical Innovation in May 2017